Gout News and Research RSS Feed - Gout News and Research

Gout is a type of arthritis that causes painful inflammation in the joints. Usually it affects one joint which is most commonly the big toe. However, it can affect any joint in the body such as the ankles, knees, wrists, elbows and any joints in the hands or finger.

Symptoms of gout usually develop rapidly and usually start at night. The joint may then start to feel normal again with any pain or discomfort eventually disappearing . However, most people who get gout will have further attacks in the future.

The symptoms of gout are caused by an above normal level of urate in the bloodstream, which builds up and forms crystals, mainly in and around joints and especially in the finger and toe joints. This can lead to intensely pain and inflammation.

There are several factors that can increase the level of blood urate. These include a diet rich in purines (which form urate when broken down) such as red meat, seafood and some other foods; excess alcohol consumption; the use of certain medicines such as diuretics; a family history of gout; kidney disease; and overweight or obesity.

Gout affects about 1% of the population and is more common in men, particularly those aged 30 to 60, and in women who have already experienced the menopause.
ESC publishes new guidelines on pericardial diseases

ESC publishes new guidelines on pericardial diseases

New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life. [More]
University of Otago research backs the belief that eating tomatoes can cause gout to flare up

University of Otago research backs the belief that eating tomatoes can cause gout to flare up

People who maintain that eating tomatoes can cause their gout to flare up are likely to welcome new research from New Zealand's University of Otago that has, for the first time, found a biological basis for this belief. [More]
TWi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

TWi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

TAIPEI, Aug. 3, 2015 /PRNewswire/ -- TWi Biotechnology, Inc., today announced that it has received Notices of Allowance for AC-201, TWi Biotechnology's lead drug candidate, from the European Patent Office and the Patent Office of the Russian Federation for patent applications numbered 11766702.2-1460 and 2012147449, respectively. [More]
Common gout medications may offer protection from alcohol-induced liver disease, inflammation

Common gout medications may offer protection from alcohol-induced liver disease, inflammation

New research in mice shows that two commonly used gout medications, which target uric acid and adenosine triphosphate, may offer protection from alcohol-induced liver disease and inflammation. [More]
3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million. [More]
Fructose stimulates reward system in the brain to a lesser degree than glucose

Fructose stimulates reward system in the brain to a lesser degree than glucose

Fructose not only results in a lower level of satiety, it also stimulates the reward system in the brain to a lesser degree than glucose. This may cause excessive consumption accompanied by effects that are a risk to health, report researchers from the University of Basel in a study published in the scientific journal PLOS ONE. Various diseases have been attributed to industrial fructose in sugary drinks and ready meals. [More]
3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006. [More]
Fewer patients take effective gout drug after steep price increase

Fewer patients take effective gout drug after steep price increase

Study finds that fewer patients with gout received useful colchicine drug after FDA actions led to 50x increase in price. [More]
Arthritis & Osteoporosis NSW to hold Clinical Update for 2015 for health professionals

Arthritis & Osteoporosis NSW to hold Clinical Update for 2015 for health professionals

Arthritis is a condition that affects over 1.1 million people in NSW and over 3 million people across Australia and with an ageing population, that figure is projected to reach 7 million by 2050. Arthritis is a condition which affects people across all ages, backgrounds, men and women alike. [More]
TWi Biotechnology obtains Rare Disease Drug designation in Taiwan for use of AC-203 to treat EBS

TWi Biotechnology obtains Rare Disease Drug designation in Taiwan for use of AC-203 to treat EBS

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received the designation of Rare Disease Drug by Taiwan FDA for use of AC-203 to treat Epidermolysis Bullosa Simplex (EBS), and is eligible for applying for coverage under National Health Insurance Administration. [More]
Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Scientists at Trinity College Dublin have uncovered a marvel molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new non-invasive treatments for arthritis, multiple sclerosis and Muckle-Wells syndrome, among a myriad of other inflammatory diseases. [More]
3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea. [More]

Hikma prepares to launch colchicine 0.6mg capsules in the US market

Hikma Pharmaceuticals PLC, the fast growing multinational pharmaceutical group, today notes that Takeda Pharmaceuticals U.S.A. Inc. has been unsuccessful in appealing the decision by the United States District Court for the District of Delaware to deny Takeda's motion for a preliminary injunction in relation to the distribution of Hikma's colchicine 0.6mg capsules for the prophylaxis of gout flares in adults. [More]
Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta Pharmaceuticals LLC, today announced that the Journal of Clinical Rheumatology published a comprehensive review of a post-hoc safety analysis that was completed for Krystexxa (pegloticase), including data from the two pivotal randomized Phase III trials and one open-label extension trial. [More]
TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received US FDA and Taiwan FDA approval of a protocol for a Phase II clinical trial of its AC-201 controlled-release (CR) tablets for the indications of high blood uric acid level and gout. [More]

Gout attacks are most common at night

Research, published today, has shown that an acute gout attack is more than twice as likely to occur during the night or early morning hours as during the day. The increased prevalence of gout attacks at night time was observed even after 24 hours with no alcohol and low purine intake. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
Montmorency cherry concentrate helps reduce effects of gout

Montmorency cherry concentrate helps reduce effects of gout

Drinking Montmorency concentrate significantly helps to reduce the effects of the painful condition gout, according to new research. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
Plant-based medication after cardiac surgery shows mixed results in reducing complications

Plant-based medication after cardiac surgery shows mixed results in reducing complications

Administration of colchicine, a plant-based medication commonly used to treat gout, before and after cardiac surgery showed mixed results in reducing potential complications from this type of surgery, but it did increase the risk of gastrointestinal adverse effects, according to a study published by JAMA. [More]
Advertisement
Advertisement